What is Linaclotide?
Linaclotide is an orally administered peptide medicine for defined constipation conditions. Its clinical outcomes concern bowel function and associated symptoms.
Biological role or research focus
Intestinal secretion in constipation care.
Age limits and dehydration warnings matter; it is not a general gut-healing peptide.
Role reference: MedlinePlus · Linaclotide ↗
Names you may encounter
Linzess
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Guanylate cyclase-C agonist
- Main research area
- Constipation-related bowel function
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Linaclotide ↗
Quick answers
- Is Linaclotide FDA approved?
- Yes. Linzess (NDA 202811, approved 2012) for IBS with constipation and chronic idiopathic constipation, and functional constipation in children. Source ↗
- Is Linaclotide safe?
- Approved gut-acting drug for chronic constipation and IBS with constipation; diarrhea is the main side effect, and it must not be used in children under 2 because of dehydration risk. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Linaclotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Chronic constipation trials (2011) | Human randomized trial | 1,276 patients across two trials. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2011
Chronic constipation trials
Two randomized trials of linaclotide for chronic constipation.
- Population / model
- 1,276 patients across two trials.
- Study design
- Twelve-week blinded comparisons of two linaclotide groups with placebo.
- Main finding
- The sustained complete-spontaneous-bowel-movement endpoint was met by roughly 16–21% of treated participants versus 3–6% with placebo across trials.
- Limits & context
- A responder had both sufficient bowel frequency and improvement from baseline over most study weeks. This is a defined constipation endpoint, not evidence of general intestinal “repair.”
Source: Two randomized trials of linaclotide for chronic constipation. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
51 registered studies name Linaclotide as an intervention; 4 are recruiting or under way, 2 have not started recruiting yet, 35 completed and 10 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Linaclotide for Colonoscopy Bowel Prep NCT06692673 · University of Florida | Terminated | Phase 1 / Phase 2 | 2025-12-01 | 4 |
| Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer NCT03796884 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Active, not recruiting | Phase 2 | 2019-10-30 | 150 |
| MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO) NCT07780344 · University of Nottingham | Not yet recruiting | Not applicable | 2026-09 | 12 |
| A Study of Virtual Reality and Linaclotide for IBS-C NCT05796388 · Mayo Clinic | Recruiting | Not applicable | 2024-05-31 | 65 |
| A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation NCT05652205 · AbbVie | Completed | Phase 3 | 2022-12-29 | 123 |
| Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis NCT07569419 · University of Nottingham | Recruiting | Early phase 1 | 2026-03-09 | 26 |
| GCC Agonist Signal in the Small Intestine NCT05107219 · University of Wisconsin, Madison | Completed | Phase 1 | 2022-11-30 | 43 |
| Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation NCT03119584 · Texas Tech University Health Sciences Center, El Paso | Active, not recruiting | Phase 4 | 2015-09-01 | 23 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 51 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Irritable bowel syndrome. ↗
Medicina clinica · 2022 Jan 21 · Journal Article, Review
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. ↗
Gastroenterology · 2023 Jun · Practice Guideline, Journal Article
Read available full text ↗
Management of Chronic Constipation: A Comprehensive Review. ↗
Internal medicine (Tokyo, Japan) · 2025 Jan 1 · Journal Article, Review
Read available full text ↗
Linaclotide. ↗
· 2012 · Review
Risks & interactions
Approved gut-acting drug for chronic constipation and IBS with constipation; diarrhea is the main side effect, and it must not be used in children under 2 because of dehydration risk.
Risk of serious dehydration in young children: in newborn mice, linaclotide caused deaths from dehydration, so it must not be used in children younger than 2 years of age.
Safety comes from FDA-approved labeling (Linzess) based on large controlled trials in adults and trials in children aged 6 to 17. There are not enough data to assess risk in children under 2.
Take extra care with: Heart or blood pressure problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Children younger than 2 years
- People with known or suspected mechanical bowel obstruction
Serious risks
- Severe diarrhea, sometimes with dizziness, fainting, low blood pressure and electrolyte problems needing hospital care
- Serious dehydration risk in very young children, based on deaths in newborn mice
Common side effects
- diarrhea
- abdominal pain
- gas (flatulence)
- bloating
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Linzess (linaclotide) prescribing information ↗
Key precautions
Diarrhea and dehydration are key concerns, and bowel obstruction is an important contraindication. Pediatric restrictions must be checked against the exact current indication.
Source: MedlinePlus · Linaclotide ↗
Regulatory status
- U.S. FDA approval
- Approved
Linzess (NDA 202811, approved 2012) for IBS with constipation and chronic idiopathic constipation, and functional constipation in children. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference covers IBS with constipation and specified constipation uses in adults and children. Eligibility and age limits vary by indication; the adult studies below are not a substitute for pediatric labeling.
Source: MedlinePlus · Linaclotide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It activates guanylate cyclase-C in the intestine and promotes intestinal fluid movement and transit. This local bowel mechanism differs from a systemic tissue-repair claim.
Source: MedlinePlus · Linaclotide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Age limits and dehydration warnings matter; it is not a general gut-healing peptide.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is it a general “gut-healing” peptide?
That is broader than the studied constipation endpoints. Symptom or bowel-frequency improvement does not prove every form of intestinal repair.
Source: MedlinePlus · Linaclotide ↗
What does “complete spontaneous bowel movement” mean?
It is a defined trial outcome involving a bowel movement without rescue medication and a sense of complete evacuation; the study sets the exact responder rule.
Source: Two randomized trials of linaclotide for chronic constipation. ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
